Related Experiment Video

Updated: Apr 29, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

mTORC2 in the center of cancer metabolic reprogramming

Kenta Masui1, Webster K Cavenee2, Paul S Mischel2

  • 1Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA; Laboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo 156-8506, Japan.

Trends in Endocrinology and Metabolism: TEM
|May 27, 2014
PubMed

Insights

Cancer cells reprogram metabolism for growth, and mechanistic target of rapamycin complex 2 (mTORC2) is key. This review explores mTORC2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Metabolic reprogramming is a hallmark of cancer, fueling tumor growth.
  • Oncogenes drive altered signaling, metabolism, and transcription in cancer.
  • Understanding these links offers new therapeutic targets and insights into drug resistance.

Purpose of the Study:

  • To review the central regulatory role of mechanistic target of rapamycin complex 2 (mTORC2) in cancer.
  • To explore mTORC2's impact on metabolic reprogramming and drug resistance.
  • To focus on mTORC2's role in glioblastoma multiforme (GBM) therapeutics.

Main Methods:

  • Literature review of recent findings on mTORC2.
  • Analysis of mTORC2's downstream effects on cellular metabolism.
  • Examination of mTORC2's influence on epigenetic modifications and therapeutic resistance.

Main Results:

  • mTORC2 plays a critical role in coordinating cancer cell metabolism.
  • mTORC2 signaling impacts epigenetic regulation and therapeutic outcomes.
  • mTORC2 is implicated in resistance to signal transduction inhibitors.

Conclusions:

  • mTORC2 is a pivotal regulator of cancer metabolism and drug resistance.
  • Targeting mTORC2 offers a promising therapeutic strategy, especially for glioblastoma.
  • Further research into mTORC2-driven metabolism is crucial for advancing cancer treatment.
Keywords:
c-Mycdrug resistanceepigeneticsglioblastomamTORC2metabolic reprogramming

More Related Videos

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

5.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.8K